XML 38 R24.htm IDEA: XBRL DOCUMENT v3.25.2
Stockholder Equity (Tables)
6 Months Ended
Jun. 30, 2025
Stockholder Equity  
Schedule of stock-based compensation expense to stock units

 

 

Three Months

 

 

Six  Months  Ended

 

 

 

June 30, 2025

 

 

June 30, 2024

 

 

June 30, 2025

 

 

June 30, 2024

 

Research and development

 

$64,837

 

 

$45,704

 

 

$128,640

 

 

$90,318

 

Compensation and related expenses

 

 

484,241

 

 

 

229,680

 

 

 

1,129,902

 

 

 

368,266

 

  Total expense

 

$549,078

 

 

$275,384

 

 

$1,258,542

 

 

$458,584

 

Schedule of stock option activity

 

 

 

 

 

 

 

 

 

 

 

Weighted

 

 

 

 

 

 

Weighted

 

 

 

 

 

Average

 

 

 

 

 

 

Average

 

 

Aggregate

 

 

Remaining

 

 

 

Shares

 

 

Exercise

Price

 

 

Intrinsic

Value

 

 

Contractual

Life (Years)

 

Options outstanding at December 31, 2024

 

 

15,843,116*

 

$0.94

 

 

$3,324,000

 

 

 

5.95

 

Granted

 

 

908,659

 

 

 

0.66

 

 

 

-

 

 

 

-

 

Exercised

 

 

(200,000 )

 

 

0.12

 

 

 

-

 

 

 

-

 

Expired/forfeit

 

 

(142,713 )

 

 

2.96

 

 

 

-

 

 

 

-

 

Options outstanding at March 31, 2025

 

 

16,409,062

 

 

$0.92

 

 

$1,274,000

 

 

 

5.98

 

Granted

 

 

1,715,152

 

 

 

0.29

 

 

 

-

 

 

 

-

 

Exercised

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

Expired/forfeit

 

 

(608,712)

 

$0.84

 

 

 

-

 

 

 

-

 

Options outstanding at June 30, 2025

 

 

17,515,502*

 

$0.86

 

 

$1,210,855

 

 

 

5.99

 

Options Exercisable at June 30, 2025

 

 

8,960,030*

 

$0.66

 

 

$1,160,000

 

 

 

3.08

 

Schedule of stock option assumtion

 

 

June 30,

 

 

June 30,

 

 

 

2025

 

 

2024

 

Expected volatility

 

67.81 – 71.56%

 

 

26.21 – 26.38%

 

Expected term (years)

 

 

6.25

 

 

 

6.25

 

Risk-free rate

 

4.00 - 4.51%

 

 

4.09 – 4.65%

 

Dividend rate

 

 

0.00%

 

 

0.00%

Schedule of outstanding nonvested restricted stock

 

 

 

 

Weighted-

Average

 

 

 

 

 

Grant Date

 

 

 

Amount

 

 

Fair Value

 

Nonvested, beginning of the year

 

 

3,549,292

 

 

$1.23

 

Granted

 

 

3,139,860

 

 

 

0.55

 

Vested

 

 

(416,333)

 

 

1.26

 

Forfeited

 

 

(60,000)

 

 

0.62

 

Nonvested, end of the year

 

 

6,212,819

 

 

$0.89

 

Schedule of stock-based compensation expense related to stock units

 

 

Three Months

 

 

Six  Months  Ended

 

 

 

June 30, 2025

 

 

June 30, 2024

 

 

June 30, 2025

 

 

June 30, 2024

 

Research and development

 

$38,363

 

 

$-

 

 

$70,332

 

 

$-

 

Compensation and related expenses

 

 

233,386

 

 

 

73,340

 

 

 

450,368

 

 

 

73,340

 

  Total expense

 

$271,749

 

 

$73,340

 

 

$520,700

 

 

$73,340

 

Schedule of warrant activity

 

 

 

 

 

 

 

 

Weighted

 

 

 

 

 

Weighted

 

 

 

 

Average

 

 

 

 

 

Average

 

 

Aggregate

 

 

Remaining

 

 

 

 

 

Exercise

 

 

Intrinsic

 

 

Contractual

 

 

 

Shares

 

 

Price

 

 

Value

 

 

Life (Years)

 

Warrants outstanding at December 31, 2024

 

 

14,675,244

 

 

$1.13

 

 

$-

 

 

 

4.88

 

Granted

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

Expired/forfeit

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

Warrants outstanding at March 31, 2025

 

 

14,675,244

 

 

$1.13

 

 

 

 

 

 

 

4.63

 

Granted

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

Expired/forfeit

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

Warrants outstanding at June 30, 2025

 

 

14,675,244

 

 

$1.13

 

 

 

 

 

 

 

 

 

Warrants exercisable at  June 30, 2025

 

 

14,675,244

 

 

$1.13

 

 

$-

 

 

 

4.39